Trial Profile
Evaluation of long-term anti-IgE antibody therapy in the patients with wheat allergy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 27 Mar 2019 Status changed from active, no longer recruiting to completed.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 18 May 2016 New trial record